Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

BETHESDA, Md., May 10, 2022 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled “Autologous Tumor Lysate-Loaded…

Click here to view original post